Supernus Pharmaceuticals, Inc.
(NASDAQ : SUPN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
PTLAPortola Pharmaceuticals, Inc. -0.31%17.906.5%$164.61m
HZNPHorizon Therapeutics Plc -1.81%49.816.5%$143.70m
CTLTCatalent, Inc. -0.52%77.332.3%$138.32m
MYOKMyoKardia, Inc. 2.30%104.651.8%$133.36m
BHCBausch Health Cos., Inc. 5.47%19.490.0%$126.05m
VRXValeant Pharmaceuticals International, Inc. 5.36%19.4714.1%$114.56m
UTHRUnited Therapeutics Corp. 1.47%119.6814.3%$76.28m
ICPTIntercept Pharmaceuticals, Inc. 2.01%73.7116.8%$60.87m
JAZZJazz Pharmaceuticals Plc 0.04%119.372.4%$60.67m
GWPHGW Pharmaceuticals Plc 2.50%125.826.2%$57.38m
AMRNAmarin Corp. Plc -2.19%6.711.6%$56.72m
ARGXargenx SE 1.70%223.020.0%$53.79m
AXSMAxsome Therapeutics, Inc. -0.97%76.231.9%$50.18m
PRGOPerrigo Co. Plc 1.88%55.806.8%$46.61m
ICLRICON plc 1.32%170.684.3%$45.03m

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.